RPTX · Insider Trading
Repare Therapeutics Inc. Common Shares
Every open-market purchase and sale reported by RPTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-28 | Carol Schafer | Director | D | −8,000 | — |
| 2026-01-28 | Ann D Rhoads | Director | D | −4,000 | — |
| 2026-01-28 | Thomas Civik | Director | D | −7,500 | — |
| 2026-01-28 | Sandra Isabelle Barros Alves | SVP, Finance and CAO | D | −31,622 | — |
| 2026-01-28 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | D | −56,786 | — |
| 2025-04-29 | Sandra Isabelle Barros Alves | SVP, Finance and CAO | A | +4,100 | — |
| 2025-04-04 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | +500,000 deriv. | — |
| 2025-03-14 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | −3,596 | −$4.10K |
| 2025-03-14 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | −21,179 | −$24.14K |
| 2025-03-14 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −5,611 | −$6.40K |
| 2025-03-14 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | −6,884 | −$7.85K |
| 2025-03-06 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | +14,000 | — |
| 2025-03-06 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | A | +14,000 | — |
| 2025-03-06 | Lloyd Mitchell Segal | PRESIDENT AND CEO | A | +40,000 | — |
| 2024-06-20 | Steven H Stein | Director | A | +54,000 deriv. | — |
| 2024-06-20 | Susan Molineaux | Director | A | +27,200 deriv. | — |
| 2024-06-20 | Ann D Rhoads | Director | A | +27,200 deriv. | — |
| 2024-06-20 | Carol Schafer | Director | A | +27,200 deriv. | — |
| 2024-06-20 | Briggs Morrison | Director | A | +27,200 deriv. | — |
| 2024-06-20 | Samarth Kulkarni | Director | A | +27,200 deriv. | — |
| 2024-06-20 | David P Bonita | Director | A | +27,200 deriv. | — |
| 2024-06-20 | Thomas Civik | Director | A | +27,200 deriv. | — |
| 2024-04-01 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | −1,614 | −$7.45K |
| 2024-04-01 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | −5,141 | −$23.78K |
| 2024-04-01 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | −800 | −$3.72K |
| 2024-04-01 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −860 | −$4.00K |
| 2024-03-27 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | −7,950 | −$37.26K |
| 2024-03-27 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −1,350 | −$6.30K |
| 2024-03-27 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | −1,500 | −$7.00K |
| 2024-03-27 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | −2,475 | −$11.56K |
| 2024-03-05 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | +14,000 | — |
| 2024-03-04 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | A | +14,000 | — |
| 2024-03-04 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | A | +14,000 | — |
| 2024-03-04 | Lloyd Mitchell Segal | PRESIDENT AND CEO | A | +40,000 | — |
| 2023-12-12 | Maria Koehler | EVP, Chief Medical Officer | M | +43,746 | +$98.76K |
| 2023-11-17 | BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | Buy | +12,273,010 | +$62.50M |
| 2023-11-03 | BIOTECHNOLOGY VALUE FUND II LP | — | Buy | +7,837,090 | +$28.21M |
| 2023-06-12 | Briggs Morrison | Director | A | +27,200 deriv. | — |
| 2023-06-12 | David P Bonita | Director | A | +27,200 deriv. | — |
| 2023-06-12 | Thomas Civik | Director | A | +27,200 deriv. | — |
| 2023-06-12 | Todd Foley | Director | A | +27,200 deriv. | — |
| 2023-06-12 | Susan Molineaux | Director | A | +76,200 deriv. | — |
| 2023-06-12 | Carol Schafer | Director | A | +27,200 deriv. | — |
| 2023-06-12 | Samarth Kulkarni | Director | A | +27,200 deriv. | — |
| 2023-06-12 | Ann D Rhoads | Director | A | +27,200 deriv. | — |
| 2023-06-09 | Michael Zinda | EVP, Chief Scientific Officer | Sell | −3,535 | −$42.55K |
| 2023-06-07 | Michael Zinda | EVP, Chief Scientific Officer | Sell | −1,200 | −$14.45K |
| 2023-02-01 | Lloyd Mitchell Segal | President and CEO | A | +78,550 | — |
| 2023-02-01 | Steve Forte | EVP, Chief Financial Officer | A | +24,530 | — |
| 2023-02-01 | Maria Koehler | EVP, Chief Medical Officer | A | +26,450 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lloyd Mitchell Segal | PRESIDENT AND CEO | 231,952 | $614.67K |
| Maria Koehler | EVP, CHIEF MEDICAL OFFICER | 227,813 | $603.70K |
| Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | 80,297 | $212.79K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RPTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.